Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $47.1 million.

  • Arcutis Biotherapeutics' Cash & Equivalents fell 6505.77% to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.1 million, marking a year-over-year decrease of 6505.77%. This contributed to the annual value of $71.3 million for FY2024, which is 1930.25% down from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Cash & Equivalents stood at $47.1 million, which was down 6505.77% from $72.7 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Cash & Equivalents ranged from a high of $288.7 million in Q1 2021 and a low of $47.1 million during Q3 2025
  • Its 5-year average for Cash & Equivalents is $96.2 million, with a median of $81.5 million in 2022.
  • In the last 5 years, Arcutis Biotherapeutics' Cash & Equivalents crashed by 7582.35% in 2022 and then surged by 13352.01% in 2024.
  • Quarter analysis of 5 years shows Arcutis Biotherapeutics' Cash & Equivalents stood at $96.4 million in 2021, then crashed by 44.38% to $53.6 million in 2022, then soared by 64.8% to $88.4 million in 2023, then fell by 19.3% to $71.3 million in 2024, then crashed by 33.95% to $47.1 million in 2025.
  • Its Cash & Equivalents stands at $47.1 million for Q3 2025, versus $72.7 million for Q2 2025 and $53.1 million for Q1 2025.